Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance

Original Submission
5 Jul 2020 Submitted Original manuscript
15 Sep 2020 Author responded Author comments - Pengfei Zhang
13 Aug 2020 Reviewed Reviewer Report
Resubmission - Version 2
15 Sep 2020 Submitted Manuscript version 2
6 Dec 2020 Author responded Author comments - Pengfei Zhang
15 Oct 2020 Reviewed Reviewer Report
5 Nov 2020 Reviewed Reviewer Report
Resubmission - Version 3
6 Dec 2020 Submitted Manuscript version 3
14 Dec 2020 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
21 Dec 2020 Editorially accepted
7 Jan 2021 Article published 10.1186/s12885-020-07754-9

You can find further information about peer review here.

Back to article page